



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2024-25/05

April 10, 2024

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - BIOCON

Subject: Intimation for the Board Meeting and Conference Call for Analysts and Investors

Dear Sir/Madam,

Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, May 16, 2024, inter alia, to approve and take on record the audited standalone and consolidated financial results of the Company for the quarter and financial year ended March 31, 2024 and to consider recommendation of dividend, if any, amongst other routine matters.

The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from Monday, April 1, 2024 to Saturday, May 18, 2024 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations, 2015. Accordingly, the trading window will open on Sunday, May 19, 2024.

The Company will organize an Earnings Conference Call for analysts/investors on Thursday, May 16, 2024. The details of the same is enclosed herewith.

The above-mentioned information will also be available on website of the Company at www.biocon.com.

Request you to take the above intimation on record.

Thanking You,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776



20th K.M. Hosur Road, Electronic City, Bangalore 560 100

April 10, 2024

Biocon's Q4 & full year FY 2024 Results Conference Call
At 18:30 hrs IST on May 16, 2024

The management team of Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will **organize a conference call for Analysts and Investors** following the announcement of financial results for the quarter and year ended March 31, 2024. The call will be conducted over Zoom.

Conference Call Details	
Date	Thursday, May 16, 2024
Time	18:30 hrs IST
Registration Link	Click here
Recording	Will be made available within 24 hrs from the end of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings)
Conference Call Transcript	Will be made available within 5 working days from the call date on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts)

Note: Participants are requested to join 10 minutes in advance of the call start time.

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

P: +91 80 2808 2040/ +91 95383 80801

E: saurabh.paliwal@biocon.com

Safe Harbor: Certain statements that may be made in the conference call may be forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and overseas, and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement made in the conference call.